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Abstract
Influenza virus A (IAV) causes annual epidemics and intermittent pandemics that affect millions of people worldwide. Potent
inflammatory responses are commonly associated with severe cases of IAV infection. The complement system, an important
mechanism of innate and humoral immune responses to infections, is activated during primary IAV infection and mediates,
in association with natural IgM, viral neutralization by virion aggregation and coating of viral hemmagglutinin. Increased
levels of the anaphylatoxin C5a were found in patients fatally infected with the most recent H1N1 pandemic virus. In this
study, our aim was to evaluate whether targeting C5 activation alters inflammatory lung injury and viral load in a murine
model of IAV infection. To address this question C57Bl/6j mice were infected intranasally with 104 PFU of the mouse
adapted Influenza A virus A/WSN/33 (H1N1) or inoculated with PBS (Mock). We demonstrated that C5a is increased in
bronchoalveolar lavage fluid (BALF) upon experimental IAV infection. To evaluate the role of C5, we used OmCI, a potent
arthropod-derived inhibitor of C5 activation that binds to C5 and prevents release of C5a by complement. OmCI was given
daily by intraperitoneal injection from the day of IAV infection until day 5. Treatment with OmCI only partially reduced C5a
levels in BALF. However, there was significant inhibition of neutrophil and macrophage infiltration in the airways, Neutrophil
Extracellular Traps (NETs) formation, death of leukocytes, lung epithelial injury and overall lung damage induced by the
infection. There was no effect on viral load. Taken together, these data suggest that targeting C5 activation with OmCI
during IAV infection could be a promising approach to reduce excessive inflammatory reactions associated with the severe
forms of IAV infections.
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Introduction
The fast activation of the complement system (CS) after a
microorganism infects a potential host is an important step in
clearance of many pathogens [1]. On the other hand, anaphyl-
atoxins like C3a and C5a, products of the CS cascade, are
commonly involved in exacerbated inflammatory reactions that
can cause direct harm to the host following infections [2,3,4].
Influenza A virus (IAV), an eight segmented, single stranded,
negative-sense RNA virus that belongs to the Orthomyxoviridae
family, [5], is known to activate the CS [6]. CS activation during
infection is thought to be important for an effective immune
response and virus neutralization in association with natural IgM
antibodies in primary infections [7]. Indeed, IAVs have developed
mechanisms of evading CS within the host, as shown by the anti-
C1q action of influenza protein M1 [8]. The pathology caused by
IAV is due mainly to excessive inflammatory responses that
culminate in lung damage and acute respiratory distress [9].
Extensive deposition of C4d was found in lungs of fatal cases of
influenza caused by IAV pandemic strains, 2009 H1N1and also
1957 H2N2 [10]. Furthermore, increased levels of C3a and C5a
had been found in bronchoalveolar lavage fluid (BALF) of mice
infected with highly pathogenic avian Influenza H5N1 but not
following seasonal IAV infection [11]. The anaphylatoxin C5a is a
strong chemoattractant for neutrophils and activates these cells to
generate oxidative burst, release of enzymes and phagocytosis
(reviewed by [12]). C5a is also able to activate macrophages and
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endothelial cells and to promote vascular leakage [12]. All these
inflammatory responses in which C5a is involved are important for
IAV-associated pneumonia. We and others have previously
described a direct relation between severity of inflammation and
lethality [13,14]. In addition, CD8+ T cell activation during
influenza infection requires C5a that acts as a chemoattractant for
T lymphocytes [15,16]. Increased levels of C5a found in BALF of
severe cases of patients infected with IAV reinforce the idea that
C5a is involved in influenza induced lung pathology [6].
Therefore, we hypothesized that preventing activation of C5
during IAV infection could decrease the magnitude of inflamma-
tion.
The co-evolution of pathogens and their hosts has generated a
plethora of molecules that increase pathogen survival [17]. We
previously described a 17 kDa lipocalin protein derived from
salivary gland of the soft tick Ornithodoros moubata, OmCI (also
known as coversin and rEV576). OmCI binds to C5 and prevents
conformational changes that lead to C5a generation and
formation of the membrane attack complex (MAC) [18,19].
OmCI is also reported to capture the inflammatory mediator
leukotriene B4 (LTB4) in a binding pocket and to have a
neutralizing effect [20,21]. The protein OmCI has been proven
active against a variety of species (mouse, rat, guinea pig, pig and
human) which has enabled it to be studied in a wide range of
animal models including asthma, immune complex lung disease
[20], coronary and renal ischaemia-reperfusion injury and sepsis
(unpublished data) and in models of autoimmune peripheral
neuropathy [21,22,23]. Phase 1 clinical trials of coversin are
currently in progress.
In this study, we used OmCI to investigate the inflammatory
response to IAV infection in mice and demonstrate that reducing
C5 activation decreases IAV mediated inflammation and pathol-
ogy without increasing viral titer within the lung.
Materials and Methods
Ethics Statement
All animal experiments were approved by CETEA/UFMG
animal ethics committee (203/08), according to Brazilian national
guidelines on animal work.
Virus
The mouse adapted virus Influenza A/WSN/33 (H1N1)-
herein named WSN - was used to infect mice as previously
described [13]. Stock virus was produced in chicken eggs and
passed once again in eggs and then cultured at a m.o.i of 0.001 in
MDCK (Madin-Darby Canine Kidney) cells grown at 37uC and
5% CO2 for 72 hours in complete Dulbeccos modified Eagle
Medium (DMEM; SIGMA) with 1 mM sodium pyruvate,
4.5 mg/ml L-glucose, 100 U/ml penicillin and 100 mg/ml strep-
tomycin, supplemented with 5% heat inactivated fetal calf serum
(FCS; CULTILAB; Brazil). Cell culture supernatants were
collected and clarified by low speed centrifugation. Virus aliquots
were frozen at –80uC until use. Viral stocks were titrated on
MDCK cell monolayers in standard plaque assays using agarose
overlay in complete DMEM with 2% FCS. Viral inoculum was
prepared by diluting the stock virus in sterile phosphate buffered
saline (PBS).
Animal infections, and treatment with OmCI and Zileuton
Male 8–10 weeks old C57BL/6J mice were maintained in
pathogen free conditions at Laborato´rio de Imunofarmacologia
(UFMG/Brazil). Prior to infection, mice were anesthetized with
ketamine/xylazine (60 mg/kg, 4 mg/kg, respectively; Syntec,
Brazil) and then received, via intranasal administration, 104 PFU
of Influenza WSN virus in sterile PBS or PBS only (Mock group) in
a total volume of 25mL. Infected mice (5 mice per group) were bled
and euthanized 1, 3 and 6 days after infection to obtain
Bronchoalveolar Lavage Fluid (BALF) and harvest lungs.
In order to evaluate the effects of OmCI during IAV infection,
mice were treated 30 minutes prior to infection with 250mg OmCI
diluted in 200 mL of PBS via intraperitoneal injection and received
further daily injections of 200 mg OmCI between days 1 to 5.
Animals in the vehicle group were injected with 200 mL PBS each
day. Weight loss was assessed daily. Five mice per group were
euthanized 1, 3 and 6 days after infection to assess leukocyte
infiltration into the airways and in lungs, levels of inflammatory
mediators in lungs or in BALF, cell free double stranded DNA
(cfDNA) in BALF, histopathological changes and viral load in
lungs.
The 5-lipoxygenase enzyme (5-LOX) inhibitor Zileuton (Zyflo,
Cornerstone Therapeutics In, USA) was used to study the role of
leukotrienes during IAV infection. 5-LOX is solely responsible for
an early step in the synthesis of leukotrienes. A group of three mice
received Zileuton from day zero to day five post-infection and
another group of five mice received a combination of Zileuton and
OmCI in the same period. Zileuton was given at a dose of 30 mg/
kg, diluted in 5% absolute ethanol (Synth, Brazil) in a solution of
Carboxymethyl Cellulose 0.5% (Synth, Brazil), via oral gavage in
200 mL.
Bronchoalveolar lavage and tissue extraction
At indicated time points, infected mice were anesthetized with a
solution of 150 mg/kg of ketamine and 10 mg/kg of xylazine and
blood was collected by the brachial plexus. Blood was allowed to
clot and centrifuged, for collection of serum, which was frozen for
further analysis. Once death was confirmed, a 1.7 mm catheter
was inserted into the trachea and bronchoalveolar lavage (BAL)
performed. To this end, the bronchoalveolar compartment was
flushed twice with 1 mL aliquots of PBS going back and forth
three times to acquire leukocytes recruited to the airways [24].
After centrifugation, the pellet was used to derive total and
differential cell counts and for FACS analysis (see below). After
BAL and perfusion of lungs with 5 mL of PBS in order to remove
circulating blood, the right lobes were removed and frozen for
quantification of Myeloperoxidase (MPO) to assess neutrophil
infiltration, inflammatory mediators and plaque assay to measure
viral load. Left lobes were fixed in formalin for histological
examination.
Measurement of MPO, inflammatory mediators and total
protein
Lung tissue (100 mg) was homogenized in PBS containing
antiproteases, as previously described [25]. MPO levels in cell
pellets were assayed using a solution of 1.6 mM tetramethylbenzi-
dine and 0.1 mM H2O2 as previously described [25]. Superna-
tants were used to assess the concentrations of IFN-c, CXCL1 and
C5a by ELISA using DuoSet kits from R&D Systems, in
accordance with the manufacturer’s instructions. BALF was also
used to quantify C5a, IFN-c and CXCL1 levels and serum was
used to quantify C5a levels using the same ELISA assay. Total
protein quantification based on Bradford’s method (Bio-Rad
Protein Assay) was performed on BALF to measure protein
leakage to airways.
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cfDNA quantification
As an indirect way to assess NETs and cell death, cfDNA was
quantified in cell-free BALF using Quant-iT PicoGreen dsDNA
quantification kit (Invitrogen) in accordance with the manufac-
turer’s instructions. Briefly, the BALF samples and a DNA
standard curve (from 1 ng/mL to 1 mg/mL) were diluted in TE
buffer and then mixed and incubated for 5 minutes with Quant-iT
PicoGreen reagent at room temperature before measuring
fluorescence (480 nm for excitation and 520 nm for emission).
Samples were compared to the standard curve and the results
expressed inmg/mL.
Flow cytometric analysis of leukocyte populations and
cell death
Leukocytes collected from airways of non-infected and infected
mice at day 6 after IAV infection were used to analyze cell death
by Annexin V staining and Propidium Iodide (PI) incorporation
(FITC Annexin V apoptosis detection kit I, BD Pharmigen),
according to the manufacturer’s instructions. The populations of
macrophages, neutrophils and lymphocytes were analyzed by
staining with fluorescent monoclonal antibodies against CD3 (PE-
Cy7, BD Biosciences, USA), CD4 (APC, BD Biosciences, USA),
CD8 (PerCP, Biolegend, USA), F4/80 (PE-Cy7, eBioscience) and
GR1 (Alexa 488, Biolegend). Stained cells were acquired in BD
LSRFortessa cell analyzer (BD Biosciences, USA) and analyzed
using FlowJo software (Tree Star, Inc., USA).
Histological analysis
Formalin-fixed left lobes of lungs were dehydrated gradually in
ethanol, embedded in paraffin, cut into 4mm sections (3 sections
per lung), stained with Hematoxylin and Eosin (H&E) and
examined under light microscopy by a pathologist blind to the
experimental procedure. All 3 sections of all left lobes were
examined and an average score assigned to each lung [26]. The
maximum score was 23 and the following parameters were
evaluated: airway inflammation (4 points), vascular inflammation
(4 points) and parenchymal inflammation (5 points), epithelial
injury (5 points) and overall neutrophilic infiltration (5 points).
Plaque assay
Lungs were collected in sterile conditions, weighed and
homogenized in PBS. The viral load in lungs were assessed on
MDCK cell monolayers, in standard plaque assays using agarose
overlay in complete DMEM with 2% FCS. Briefly, MDCK cell
monolayers, in 6 well plates, were incubated for 60 minutes with
serial 10-fold dilutions of lung homogenates at 37uC and 5% of
CO2, when the agarose monolayer was added. After additional
72 hours of incubation, agarose overlays were removed, the cells
where fixed in formalin and stained with crystal violet. The viral
titer was expressed as plaque forming unit (PFU) per gram of
tissue.
Statistical analysis
All data are presented as the mean 6 SEM and were analyzed
using One-way analysis of variance followed by Newman-Keuls
post-test to compare different groups. Unpaired t test was used to
compare two groups. Statistical significance was set as P,0.05 and
all graphs and analysis were performed using Graph Pad Prism 4
software.
Results
Local complement activation after Influenza virus A (IAV)
infection
Complement activation following IAV infection has been found
to be correlated with clinical disease severity [6,10,27]. Thus,
aiming to assess complement activation in our system, we infected
C57BL6/J mice with 104 PFU of the mouse-adapted Influenza
WSN virus. We collected blood, performed bronchoalveolar
lavage (BAL) and lungs were harvested 1, 3 and 6 days after
infection. We found significantly increased C5a levels in BALF of
IAV infected animals from the third to the sixth day of infection,
peaking at day 6 after infection (Figure 1, left). By contrast, C5a
levels in lung homogenates after infection were similar to mock
group at all time points after infection (data not shown), and serum
levels of C5a increased at the first day of infection and decreased at
day six (Figure 1, right).
Figure 1. Effects of IAV infection on C5a levels in BALF (left) and serum (right). C57BL/6J mice were infected intranasally with 104 PFU of
Influenza A/WSN/33 H1N1, or received PBS intranasally (Mock group). At the indicated time points after infection 5 mice per group were euthanized,
blood was collected and BAL performed. Serum and BALF concentrations of C5a were measured by ELISA. Data are presented as Mean 6 SEM. *, **
and *** for p,0.05, p,0.01 and p,0.001 respectively, when compared to Mock group or indicated group (One-way ANOVA, Newman-Keuls Multiple
Comparison test).
doi:10.1371/journal.pone.0064443.g001
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Treatment with OmCI decreases C5a levels, neutrophil
and macrophage accumulation and protein leakage after
IAV infection
In order to evaluate a possible role of C5a for the inflammatory
responses caused by IAV infection, infected mice were treated with
the protein OmCI that binds to C5 and prevents generation of
C5a and formation of the membrane attack complex (MAC).
Infection with IAV induced an intense influx of leukocytes (Figure
2A) in the airway spaces that peaked at day 6 after infection. The
inflammatory infiltrate was predominantly composed of neutro-
phils (Figure 2B) that were present in high number from the third
day after infection and macrophages (Figure 2C) that peaked at
day six. Lymphocytes were found in significantly elevated numbers
only 6 days after infection (Figure 2D). Protein levels in BALF, a
sign of increased vascular permeability [28], were increased from
the third day after infection and greatly increased by day 6 (Figure
2E). There was also significant infiltration of neutrophils in lungs
of vehicle treated, infected mice as assessed by MPO quantification
(Figure 3A) or histopathological analysis (Figure 3B–E; asterisks).
When IAV-infected mice were treated with OmCI, the total
number of leukocytes (Figure 2A), neutrophils (Figure 2B) and
macrophages (Figure 2C) were reduced in BALF when compared
to vehicle treated group at day 6 after infection. This was also
confirmed when leukocyte types were evaluated by flow cytometry
(data not shown). The number of lymphocytes in BALF of OmCI-
treated mice was similar to that of vehicle treated mice (Figure
2D). Protein leakage at day six after IAV infection was reduced in
OmCI treated mice, when compared to vehicle group (Figure 2E).
Inhibition of neutrophil influx into the airways of OmCI-treated
animals was not associated with decrease in accumulation of these
cells in lung parenchyma, as assessed by MPO levels (Figure 3A)
and histopathological analysis (Figure 3B-E). Both OmCI treated
and control mice inoculated with IAV displayed similar weight loss
(23.1%66.2% versus 22.5%64.6%, respectively).
IAV infection induced a significant increase in levels of C5a
(Figure 4A) and the chemokine CXCL1 (Figure 4B) in BALF and
levels of CXCL1 (Figure 4C) and IFN- c (Figure 4D) in lung
homogenates. After OmCI administration into IAV-infected mice,
levels of CXCL1 (Figure 4C) and IFN- c (Figure 4D) were similar
to those found in the vehicle group, while C5a levels were partially
reduced (Figure 4A). There was very significant inhibition of
CXCL1 levels in BALF in OmCI treated mice 3 days after
infection (Figure 4B).
Effects of OmCI treatment on lung damage caused by
IAV infection
Histopathological analysis of lung slides showed that, after 6
days of IAV infection, there was significant inflammatory
infiltration in peribronchiolar and perivascular areas in addition
Figure 2. Effects of C5 activation inhibitor OmCI during IAV
infection on leukocyte transmigration and protein leakage.
C57BL/6J mice were infected intranasally with influenza or Mock
infected as described in Figure 1. OmCI treated mice received the
protein prior to IAV infection and daily thereafter, while vehicle group
received PBS, until one day before the indicated time point. At the 1, 3
and 6 days after infection, mice were euthanized and BAL performed. A)
Total number of leukocytes, B) number of neutrophils and C) number of
macrophages, D) number of lymphocytes recovered from the airways;
E) total protein quantification in BALF. Data are presented as Mean 6
SEM. *, ** and *** for p,0.05, p,0.01 and p,0.001 respectively, when
compared to Mock group; # and ## for p,0.05, p,0.01 respectively,
when compared to Vehicle group sampled on the same day (One-way
ANOVA, Newman-Keuls Multiple Comparison test).
doi:10.1371/journal.pone.0064443.g002
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to bronchial epithelial damage and parenchymal inflammation.
Focal inflammatory infiltrates composed of mononuclear cells and
neutrophils were visualized in the septa and alveolar lumen (Figure
5D, E, F) while normal lungs of PBS instilled mice (Mock group)
did not present these alterations (Figure 5A, B, C). Remarkably,
the overall appearance of the lung of OmCI-treated animals was
better than that of vehicle-treated animals and this was reflected in
an overall amelioration of pathological scores (Figure 5G, H, I, J).
We also used a score system (Figure 5 J) which measures individual
airways (a), vascular (v) and parenchymal inflammation (p) as well
as neutrophil infiltration (asterisks) and epithelial injury (arrow-
heads, Figure 3 D, E). In all the evaluated parameters vehicle-
treated IAV infected group had a higher score compared to Mock
group, but OmCI-treated IAV infected group presented reduced
vascular and parenchymal inflammation and also lower epithelial
injury. Thus, overall pathologic scores, on a 23 points scale, were
reduced in OmCI (8.061.1) when compared to vehicle treated
group (14.561.2), Figure 5 J.
Effects of OmCI treatment on cfDNA and cell death
caused by IAV infection
NETs are composed of DNA fibers and cytoplasmic proteins
and released by neutrophils during infections to kill bacteria, fungi
or protozoa [29]. However, NETs may also contribute to tissue
damage [30]. The quantification of cell free double-stranded DNA
(cfDNA) in BALF is an indirect way to quantify NETs [31] and
showed that IAV infection leads to increased cfDNA content from
day 3 that continues to increase to day 6 after infection (Figure
6A). Treatment with OmCI was associated with significant
reduction in cfDNA levels in BALF at day 6 but not day 3 after
infection (Figure 6A).
Cell free DNA can also be found as a result of late apoptosis or
necrosis [32]. So, we analyzed whether OmCI treatment affected
cell death known to be induced by IAV infection [33]. We
analyzed Annexin V binding and PI incorporation in leukocytes
recovered from the airways. Indeed, IAV infection caused
increased numbers of apoptotic (Annexin V+ PI-, Figure 6B),
but also necrotic (or late apoptotic, Annexin V+ PI+, Figure 6C)
leukocytes. OmCI treatment resulted in diminished number of
necrotic (Figure 6C) but not apoptotic cells (Figure 6B).
Figure 3. Neutrophil accumulation in lung parenchyma of vehicle and OmCI treated mice. C57BL/6J mice were infected and assigned to
treatment groups as in Figure 2. At 1, 3 and 6 days after infection, mice were euthanized, lungs harvested and MPO assayed, to measure neutrophil
accumulation in tissue. A) Relative numbers of neutrophils in lungs. At day 6, lungs were harvested for assessment of neutrophil infiltration by
analysis of H&E stained lung slides. B) Pathologic score (0–5) of neutrophil accumulation in lungs performed by a pathologist. Representative slides of
H&E stained lungs of a C) mock mouse; D) vehicle mouse; E) OmCI treated mouse. Asterisks indicate areas with neutrophils infiltration and
arrowheads indicate bronchial epithelial damage. Data are presented as Mean 6 SEM. * and *** for p,0.05 and p,0.001, respectively, when
compared to Mock group (One-way ANOVA, Newman-Keuls Multiple Comparison test). Bars represent 100 mm.
doi:10.1371/journal.pone.0064443.g003
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OmCI treatment does not alter the titer of IAV
Complement is a crucial host system that is activated during
influenza virus infection and plays an important role in viral
clearance [34]. The anaphylatoxin C5a, which is highly
chemoattractant to neutrophils [12], is also chemoattractant to
T lymphocytes [15] and is important for effective anti-IAV activity
mediated by CD8+ T cells [35]. Although differential cell counts
showed the same number of lymphocytes in vehicle and OmCI
treated mice at day 6 after infection (Figure 2 E), further analysis of
lymphocyte populations by FACS showed that CD8+ T cells, that
are increased in the airways after IAV infection are present in
lower numbers in OmCI treated mice (Figure 7A). This difference
is not found in CD4+ T cells subset (data not shown). However,
despite reduction in CD8+ T cells, viral titers in lungs of mice
infected with IAV was not altered by treatment with OmCI
(Figure 7B), which suggests viral clearance was unaffected by
OmCI.
Treatment with Zileuton, a 5-LO inhibitor, does not alter
IAV-associated pulmonary inflammation
In order to assess whether the LTB4 binding ability of the
protein OmCI accounts for its properties during IAV infection, we
used Zileuton, a 5-LOX inhibitor, alone or in combination with
OmCI. If LTB4 binding by OmCI accounts for the anti-
inflammatory activity of OmCI in this model, Zileuton should
inhibit IAV associated pulmonary inflammation as effectively as
OmCI. After IAV infection, Zileuton treatment or combination of
Zileuton and OmCI did not change leukocyte recruitment to the
airways (Figure 8A, B) or viral loads (Figure 8D), when compared
to vehicle treated mice. The combined treatment of Zileuton and
OmCI, but not Zileuton alone, induced similar effects to that of
OmCI treatment in cfDNA levels (Figure 8C), which indicates that
LTB4 might not be involved in OmCI effects.
Discussion
Medical concern about IAV pandemics and epidemics faces the
challenge of new viral influenza strains that may become resistant
to antivirals [36]. For this reason, anti-inflammatory strategies
targeting excessive activation of the innate immune system may be
a useful adjunctive therapy against IAV infection [13,37]. We
demonstrate here that an arthropod derived inhibitor of C5
activation decreases the recruitment of neutrophils and macro-
phages to the alveolar space and reduces consequent epithelial
damage and lung pathology in IAV infected mice. We also show
that reduction of lung inflammation by OmCI did not reduce viral
clearance.
A recent paper from O’Brien and colleagues (2011) detected
increased C3a and C5a levels in BALF of mice infected with a
highly pathogenic H5N1 avian Influenza virus, VN/1194 but not
in BALF of animals inoculated with low virulent seasonal or 2009
pandemic viruses [11]. Using the mouse adapted IAV strain A/
WSN/33, that mimics a model of severe infection [38] to study
innate immune response to the virus we found an increase in C5a
levels during the course of infection. O’Brien and colleagues (2011)
showed that C3 plays a protective role during IAV infection using
a C3 KO mouse strain that showed more severe lung inflamma-
tion, weight loss and increased viral load than wild type mice. The
protective role of C3 in IAV infection might be explained by the
Figure 4. Inflammatory mediator levels after IAV infection. C57BL/6J mice were infected and assigned to treatment groups as in Figure 2. At
1, 3 and 6 days after infection, mice were euthanized, BAL performed and lungs harvested. BALF concentrations of C5a (A), CXCL1 (B) and pulmonary
concentrations of CXCL1 (C), and IFN-c (D) were measured by ELISA. Data are presented as Mean 6 SEM. ** and *** for p,0.01 and p,0.001
respectively, when compared to Mock group;# and### for p,0.05 and p,0.001 respectively, when compared to vehicle group sampled on same
day (One-way ANOVA, Newman-Keuls Multiple Comparison test).
doi:10.1371/journal.pone.0064443.g004
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Figure 5. Histopathologic changes caused by IAV are reduced in OmCI treated mice. C57BL/6J mice were infected and assigned to
treatment groups as in Figure 2. At the sixth day after infection, mice were euthanized and lungs harvested. Representative slides of H&E stained
lungs of mock (A, B, C); vehicle (D, E, F); and OmCI treated mice (G, H, I). ‘‘p’’ represents parenchyma, ‘‘v’’ represents vessels and ‘‘a’’, airways. Asterisks
indicate foci of inflammatory infiltrates and arrowheads indicate areas of epithelial injury. (J) Histopathological score (maximal of 23) evaluated
airway, vascular, parenchymal inflammation, neutrophilic infiltration and epithelial injury. Data are presented as Mean 6 SEM. *, ** and *** for
p,0.05, p,0.01 and p,0.001 respectively, when compared to Mock group; # and ## for p,0.05, p,0.01 respectively, when compared to Vehicle
group (One-way ANOVA, Newman-Keuls Multiple Comparison test). Bars represent 100 mm.
doi:10.1371/journal.pone.0064443.g005
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ability of C3a to down-regulate regulatory T cell population and
antigen-specific Th17 cells observed in a model of allergic lung
inflammation [39]. Furthermore, in a model of IgG immune-
complex deposition, C3 deficient mice developed marked lung
injury that diminished with C5a blockade [40], suggesting that
C5a has a more pathogenic role during inflammation than C3 and
its products. This pathogenic role of C5a can be explained by its
greater ability to stimulate chemotaxis, granule release and
superoxide production in neutrophils than C3a even in low
concentrations [41]. The activation of macrophages and endothe-
lial cells by C5a to promote vascular leakage [12], and
consequently protein accumulation in the airways, may also
explain the protection found after OmCI treatment. Moreover, in
vitro studies demonstrated that C5a, in association with GM-CSF,
is able to induce the release of NETs [42]. It was recently reported
that NETs are produced during IAV infection and are associated
with alveolar damage in IAV induced pneumonitis [43]. We
observed that IAV-induced cfDNA, an index of NETs formation,
was reduced after OmCI treatment (Figure 6), and is coincident
with reduced lung damage after infection in OmCI treated mice
(Figure 5). It is of note that OmCI treatment also reduced number
of dead cells in the BAL of infected animals. As dead cells may
directly contribute to an increase in cfDNA, the effects of OmCI
on cell death may also contribute to the decrease of this parameter,
in addition to any possible effect on NET formation.
We found reduced neutrophil and macrophage transmigration
and reduced protein leakage in alveolar spaces but no change in
the number of neutrophil in lungs of OmCI treated mice (Figures
2 and 3). Accumulation of neutrophils in different lung compart-
ments requires different mechanisms, and the migration of
neutrophils to the airways after crossing the epithelial layers is
known to be critical for the induction of lung injury [44]. For
example, we have previously shown that, in a model of pulmonary
fibrosis induced by bleomycin, the blockade of CXCR2, the
chemokine receptor involved in neutrophil chemotaxis, led to
reduced neutrophil number in BALF and protection from lung
fibrosis, but there was still neutrophil accumulation in lungs at a
later time point [25]. Blockade of neutrophil and macrophage
influx into the airways, accompanied by lower protein leakage by
OmCI treatment with consequent reduction in NETs formation,
cellular death and epithelial damage may explain the beneficial
effects of the protein during IAV infection.
OmCI, also known as coversin and rEV576 is a recombinant
small protein belonging to the lipocalin super-family [19] and has
a circulating half-life of 30 hours when bound to C5 [18]. It is
derived from a native protein discovered in the saliva of the soft
tick Ornothodoros moubata where its function appears to be to assist
the parasite to feed without provoking a host immune response.
OmCI has been found to prevent in a dose-related manner the
cleavage of complement C5 of all species that it has been tested,
including mouse, rat, guinea pig, pig and human [18,19,23].
The use of complement antagonists during viral infections faces
the challenge of possible impairment of pathogen clearance due to
ineffective immune responses against the virus [45]. Reduced
levels and activity of specific T CD8 cells were found in mice
treated with a C5aR antagonist [35] and C3 deficient mice
presented reduced T cell activity and increased viral levels after
IAV infection [34]. Nevertheless, here we showed that partially
reducing C5a levels through the use of a C5 binding protein
during IAV infection indeed reduced CD8+ T cells, but did not
affect host response against the virus. Normal viral loads and IFN-
c levels were found in OmCI treated mice, suggesting that the
ability of the host to deal with the virus was unaffected. However,
Figure 6. Effects of OmCI on cfDNA levels and number of dead
cells in BALF after IAV infection. C57BL/6J mice were infected and
assigned to treatment groups as in Figure 2. At1, 3 and 6 days after
infection, mice were euthanized and BAL was performed. A) Cell free
DNA (cfDNA) levels were measured in BALF by the Quant-iT PicoGreen
dsDNA quantification kit. At six days after infection, leukocytes
recovered from airways of Mock, Vehicle and OmCI treated mice were
analyzed for cellular death by Annexin V and PI incorporation. B) Total
apoptotic leukocytes, Annexin V+ PI-, in BALF; C) Total necrotic or late
apoptotic leukocytes, Annexin V+ PI+, in BALF. Data are presented as
Mean 6 SEM. ** and *** for p,0.01 and p,0.001 respectively, when
compared to Mock group; # and ## for p,0.05, p,0.01 respectively,
when compared to Vehicle group (Kruskal-Wallis test, Dunn’s Multiple
Comparison post-test).
doi:10.1371/journal.pone.0064443.g006
Figure 7. Number of CD8+ T cells and pulmonary viral load
after IAV infection and OmCI treatment. C57BL/6J mice were
infected and assigned to treatment groups as in Figure 2. A) Numbers
of CD3+ CD8+ cells recovered by BAL and analyzed by FACS are
reduced in OmCI treated group 6 days after infection. ** and *** for
p,0.01 and p,0.001 respectively, when compared to Mock group; #
for p,0.05, when compared to Vehicle group (Kruskal-Wallis test,
Dunn’s Multiple Comparison post-test). B) Viral titers 6 days after
infection in lungs homogenates shown are not changed between
vehicle and OmCI treated groups, as assessed by MDCK plaque
formation (Unpaired t test).
doi:10.1371/journal.pone.0064443.g007
The Role of C5 Activation in Influenza A Infection
PLOS ONE | www.plosone.org 8 May 2013 | Volume 8 | Issue 5 | e64443
inflammation and tissue injury caused by the infection were
reduced by OmCI treatment. The concept that there are
mediators which contribute to tissue injury but not to host
resistance may be useful from a therapeutic point of view [46].
Indeed, our group has provided several proof of concept studies
demonstrating the beneficial role of blocking certain aspects of
inflammation for the outcome of infection in several animal
models, including those caused by bacteria [47], IAV [13], other
viruses [48] or protozoan [49].
The molecule CD59a, is a natural regulator of the MAC. It was
demonstrated that CD59a KO mice infected with IAV present
exacerbated lung inflammation associated with enhanced activa-
tion of MAC, excessive neutrophil numbers and death, despite
increased virus specific CD4 T cell responses [50]. This latter
finding supports our studies by suggesting that excessive C5
activation may cause unwanted inflammation in the context of
IAV infection. Furthermore, the latter study suggests that the
ability of OmCI to reduce MAC formation [19] may contribute to
the observed effects in our model, in addition to an effect on C5a
production.
Besides its action in preventing C5 cleavage, OmCI has a
neutralizing effect over LTB4 [20,23]. This property of OmCI
could potentially contribute to its effects on IAV infection, as
LTB4 is a potent neutrophil chemoattractant in its own right.
However, treatment of mice with an inhibitor of 5-LO, the
enzyme responsible for LTB4 formation, showed that this pathway
appears to have little effect in the context of IAV infection. A
recent study showed that treatment of mice with a human C5a
agonist protected mice from lethality caused by IAV infection by
enhancing neutrophil, dendritic cell and NK cell populations [51].
The authors used a small synthetic polypeptide from C5a, called
EP67, engineered to eliminate the anaphylactic activity of C5a,
because it lacks the ability to bind C5aR (CD88) on neutrophils
but can directly activate C5aR on other cells such as APC.
Therefore, the authors used a pharmacological strategy to enhance
the innate anti-viral immune responses without enhancing viral-
associated inflammation. We used a compound which prevents
C5a formation, which was associated with decreased neutrophil
influx and associated damage. Therefore, although these studies
are apparently contradictory, both molecules – EP67 and OmCI –
have been engineered to cause reduced inflammation with
enhanced (EP67) [51] or unaltered (OmCI) anti-viral immunity.
It is possible that the role of complement in preventing excessive
inflammation during IAV infection may be virus strain specific or
dependent on the particular host. Only studies in humans
naturally infected with different strains and subtypes could address
this possibility. Notably, other studies using different therapeutic
agents have reported benefits associated with decreasing excessive
cell influx – macrophages, neutrophils, DCs, CD4 and CD8 T
cells – during influenza virus infections (reviewed by [52]).
Figure 8. Leukocyte recruitment and cfDNA levels in BALF after IAV infection upon OmCI and Zileuton treatment. C57BL/6J mice were
infected intranasally with 104 PFU of Influenza A/WSN/33 H1N1, or received PBS intranasally (Mock group). The 5-LO inhibitor Zileuton (30 mg/kg)
was given alone or in combination with OmCI. Mice received the treatment prior to the infection and daily until day 5 after infection, while vehicle
group received PBS both, via i.p, Zileuton was given by oral gavage. At the sixth day after infection, mice were euthanized, BAL performed and lungs
were harvested. A) Total number of leukocytes; B) number of neutrophils; C) cfDNA levels measured in BALF. Data are presented as Mean 6 SEM. *
and *** for p,0.05 and p,0.001 respectively, when compared to Mock group; # and ## for p,0.05, p,0.01 respectively, when compared to
Vehicle group (One-way ANOVA, Newman-Keuls Multiple Comparison test).
doi:10.1371/journal.pone.0064443.g008
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Therefore, the hypothesis that decreasing unwanted inflammation
during IAV infection may be beneficial is potentially of interest but
needs to be addressed adequately in clinical trials in humans.
The involvement of C5 in many diseases could be studied in a
wide range of animal models including asthma, immune complex
lung disease, coronary and renal ischemia-reperfusion injury
(unpublished data) and in models of autoimmune peripheral
neuropathy, using the treatment with OmCI [21,22]. Phase 1
clinical trials of coversin are currently in progress. If it proves to be
safe and effective in blocking the terminal common pathway of the
complement cascade in humans there is a possibility that it may
prove to be a useful therapeutic agent in the treatment of lung
inflammation caused by IAV infection.
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